Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Finch Therapeutics Group, Inc. FNCH
$0.38
+$0.01 (1.97%)
На 18:04, 12 мая 2023
+4 373.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
21577416.00000000
-
week52high
3.00
-
week52low
0.30
-
Revenue
861000
-
P/E TTM
0
-
Beta
0.02143500
-
EPS
-2.17000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 09 авг 2022 г. | |
| Jefferies | Buy | Buy | 04 апр 2022 г. |
| Jefferies | Buy | 13 апр 2021 г. | |
| Evercore ISI Group | Outperform | 13 апр 2021 г. | |
| B of A Securities | Buy | 13 апр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Blaustein Marc | D | 32614 | 3636 | 21 окт 2022 г. |
| Vittiglio Joseph | D | 31364 | 3636 | 21 окт 2022 г. |
| Shumway Chris | A | 44843 | 44843 | 13 июн 2022 г. |
| Blaustein Marc | A | 36250 | 35000 | 13 июн 2022 г. |
| Lange Christian H. | A | 44843 | 44843 | 13 июн 2022 г. |
| Graf Susan E | A | 44843 | 44843 | 13 июн 2022 г. |
| FERRANTE DOMENIC J | A | 44843 | 44843 | 13 июн 2022 г. |
| Vittiglio Joseph | A | 35000 | 35000 | 13 июн 2022 г. |
| Hamood Samuel A | A | 44843 | 44843 | 13 июн 2022 г. |
| Haft Nicholas | A | 44843 | 44843 | 13 июн 2022 г. |
Новостная лента
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 09:47
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Zacks Investment Research
05 сент 2022 г. в 13:33
Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
GlobeNewsWire
09 мая 2022 г. в 08:22
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.
Why Finch Therapeutics Stock Is Skyrocketing Today
The Motley Fool
29 апр 2022 г. в 12:10
The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
InvestorPlace
29 апр 2022 г. в 12:10
Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?